1. Introduction {#sec1}
===============

Cycloplatinated imines and related compounds have been widely studied because of their relevance in C--H activation, organometallic reactivity, and structural peculiarity and their utility as metallomesogens and luminescent materials.^[@ref1]−[@ref10]^ Various Pt(II) precursors have been used to cycloplatinate N-donor ligands of which a mixture of *cis*-\[PtCl~2~(DMSO)~2~\] and NaOAc was shown to be the most convenient one for successful cycloplatination.^[@ref1]−[@ref5],[@ref8]−[@ref12]^ The OAc^--^ in cycloplatination is believed to play a dual role as a nucleophile and as a base. Wu and co-workers hypothesized that cycloplatination of ferrocenylimine with *cis*-\[PtCl~2~(DMSO)~2~\] in the presence of NaOAc in toluene proceeds via a bicyclic transition state that contained a coordinated OAc.^[@ref7]^ The formation of an acetate-substituted product before cycloplatination of amino imines with a mixture of *cis*-\[PtCl~2~(DMSO)~2~\] and NaOAc was detected by ^1^H NMR spectroscopy,^[@cit5b]^ and such a product was isolated in a very minor amount in one instance but without the knowledge that this is one of the intermediates in OAc^--^-assisted cycloplatination.^[@ref13]^ The study aimed at understanding an intricate mechanism of cycloplatination of N-donor ligands in the absence of an external base is also being pursued.^[@ref14],[@ref15]^

Guanidines and N-substituted guanidines were shown to act as neutral and anionic N-donor ligands, respectively, exhibiting chelating and bridging coordination modes in structurally characterized Pt(II) complexes.^[@ref16]−[@ref23]^ For the first time, *sym N*,*N*′,*N*″-triarylguanidines, \[ArN=C(NHAr)~2~\] (sym = symmetrical; Ar = Me-/OMe-substituted aryl rings), were cycloplatinated with a mixture of *cis*-\[PtCl~2~(DMSO)~2~\] and NaOAc, thereby affording six-membered cycloplatinated *N*,*N*′,*N*″-triarylguanidines, \[Pt{κ^2^(*C*,*N*)}Cl(DMSO)\] (**A**). During the course of syntheses of **A**, *cis*-/*trans*-\[PtCl~2~(DMSO){ArN=C(NHAr)~2~}\] (**B**) and acetate-substituted product, *cis*-\[Pt(OAc)Cl(DMSO){ArN=C(NHAr)~2~}\] (**C**), were also isolated, and the latter product was shown to be one of the intermediates for **A**.^[@ref24]^ The isolation of **C** partly corroborated the hypothesis put forward by Wu, Crespo, and co-workers for the mechanism of cycloplatination of N-donor ligands mediated by NaOAc.^[@cit5b],[@ref7]^ Recently, Vázquez-García, Vila, and co-workers have shown through density functional theory calculations that during the cycloplatination of hydrazine-based N-donor ligands with a mixture of *cis*-\[PtCl~2~(DMSO)~2~\] and NaOAc, indeed acetate enters into the coordination sphere of Pt(II) and forms a Wheland intermediate before forming terdentate-cycloplatinated hydrazine, \[Pt{κ^3^(*C*,*N*,*N*)}Cl\].^[@ref25]^

Carboxylate-assisted C--H activation of transition metals has been intensively investigated through both experimental and computational techniques.^[@ref26]^ We cycloplatinated *sym N*,*N*′,*N*″-triarylguanidines with *cis*-\[PtX~2~(DMSO)~2~\] (X = OC(O)R; R = Me and CF~3~) with a view aimed at understanding the influence of carboxylates in these precursors upon the structural motifs of the resulting products. The difference in size of carboxylate moieties in the aforementioned precursors allowed us to isolate two distinct families of six-membered cycloplatinated guanidines, namely, **1--3** and **4--7**; the motifs present in these platinacycles were determined by single-crystal X-ray diffraction (SCXRD) and are unprecedented in the literature. Further, **8** and **9** were successfully transformed to six-membered cycloplatinated guanidines **10** and **11**, respectively, through a pathway, which is unprecedented in the literature.

2. Results and Discussion {#sec2}
=========================

2.1. Syntheses of Pt(II) Precursors {#sec2.1}
-----------------------------------

*trans*-\[PtCl~2~(PhCN)~2~\] and *cis*-\[PtX~2~(DMSO)~2~\] (X = Cl and OAc) were prepared in yields greater than the literature yields as outlined in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00782/suppl_file/ao8b00782_si_001.pdf).^[@ref9],[@ref27]−[@ref29]^ The metathesis reaction of *cis*-\[PtCl~2~(DMSO)~2~\] with 2 equiv of AgTFA in CH~2~Cl~2~ at room temperature (RT) for 24 h afforded *cis*-\[Pt(TFA)~2~(DMSO)~2~\] in 91% yield, as illustrated in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.
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2.2. Syntheses of Cycloplatinated Guanidines and Plausible Mechanism {#sec2.2}
--------------------------------------------------------------------

The reactions of *cis*-\[Pt(OAc)~2~(DMSO)~2~\] with 2 equiv of \[ArN=C(NHAr)~2~\] (Ar = 2-MeC~6~H~4~ (LH~2~^2-tolyl^) and 2,4-Me~2~C~6~H~3~ (LH~2~^2,4-xylyl^) carried out separately in toluene under reflux condition for 8 h afforded **1** and **2** as colorless crystalline materials in 82 and 84% yields, respectively (see [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The aforementioned reaction carried out with \[ArN=C(NHAr)~2~\] (Ar = 2-(MeO)C~6~H~4~; LH~2~^2-anisyl^) afforded only Pt black as a decomposition product, most likely due to greater basicity of the guanidine. The salt metathesis reaction of **1** with AgTFA in CH~2~Cl~2~ at RT for 24 h afforded **3** as a colorless crystalline material in 94% yield.

![](ao-2018-00782z_0018){#sch2}

The reactions of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] with 1 equiv of LH~2~^2-tolyl^ and its 4-tolyl analogue, LH~2~^4-tolyl^ and LH~2~^2,4-xylyl^, carried out separately in toluene under reflux condition for 8 h afforded **4--6** as colorless crystalline materials in 78, 73, and 83% yields, respectively (see [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). The reaction of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] with 1 equiv of LH~2~^2-anisyl^ in toluene under reflux condition for 8 h followed by slow cooling of the reaction mixture afforded \[LH~3~^2-anisyl^\]TFA as a colorless crystalline material in low yield. Removal of volatiles from the reaction mixture and subsequent crystallization of the resulting solid in ethanol afforded **7** in 36% yield. The yields of **7** and \[LH~3~^2-anisyl^\]TFA increased to 74 and 81%, respectively, when the aforementioned reaction was repeated with the Pt/guanidine ratio of 1:2 under otherwise identical condition. The precipitation of the guanidinium salt only in this reaction is probably ascribed to the greater basicity of LH~2~^2-anisyl^. The reaction of *cis*-\[Pt(OAc)~2~(DMSO)~2~\] with 1 equiv of LH~2~^2-tolyl^ and the reaction of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] with 2 equiv of the same guanidine under the condition identical to that mentioned in [Schemes [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} and [3](#sch3){ref-type="scheme"} afforded **1** and **4** in 38 and 81% yields, respectively. This outcome suggests that it is the nature of Pt(II) precursors and not the Pt/guanidine ratio, which determines motifs in cycloplatinated guanidines.
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*trans*-\[PtCl~2~(PhCN)~2~\] was treated with 2 equiv of LH~2~^2-tolyl^ and LH~2~^2,4-xylyl^ separately in toluene under reflux condition for 48 h to afford **8** and **9** in 90 and 45% yields, respectively, after column chromatographic work-up on basic alumina using CHCl~3~ as the eluent (see [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). The aforementioned reaction carried out with *cis*-\[PtCl~2~(DMSO)~2~\] and LH~2~^2-tolyl^ under otherwise identical condition did not yield **8**, presumably because of the difference in steric/electronic factors around Pt(II) in the precursor.
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The presence of variable number of guanidines in **1--2** and **4--7** stimulated us to isolate plausible intermediates such as **D** and **E**, respectively (see [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The reaction of **8** with 2 equiv of AgOAc and the reaction of *trans*-\[PtCl~2~(DMSO){ArN=C(NHAr)~2~}\] (Ar = 2-MeC~6~H~4~^24^) with 2 equiv of AgTFA in CH~2~Cl~2~ at RT for 24 and 3 h afforded **1** and **4** instead of **D** and **E**, respectively. The formation of **1** and **4** in the aforementioned reactions was confirmed by thin-layer chromatography (CHCl~3~/MeOH; v/v 60/40) and ^1^H NMR spectroscopy and through the isolation of **1** in 90% yield (see [Method 1 [4.12.1](#sec4.12.1){ref-type="other"}](#sec4.12.1){ref-type="other"} under reactivity of **8** in [Experimental Section](#sec4){ref-type="other"}). The reaction of **8** with 2 equiv of NaOAc in MeOH for 8 h under reflux condition also afforded **1** in 90% yield instead of **D** (see [Method 2 [4.12.2](#sec4.12.2){ref-type="other"}](#sec4.12.2){ref-type="other"}). The elusive nature of **D** from our attempts suggests that unless the N-donor ligand such as guanidine is sterically protected as illustrated through the isolation of *trans*-\[Pd(OC(O)R)~2~L~2~\] (R = Me, Ph, and ^*t*^Bu; L = \[ArN=C(NHAr)~2~\]; Ar = 2,5-Me~2~C~6~H~3~ (LH~2~^2,5-xylyl^)),^[@ref30]^ cycloplatination would eventually occur even at RT because of the availability of both the acetate and the guanidine ligands in proximal position. The reaction of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] with *sym N*,*N*′,*N*″-triarylguanidines either in 1:1 or 1:2 Pt/guanidine ratio can afford only the intermediate **E** and not the intermediate of type **D** because of steric reasons.

![Proposed intermediates **D** and **E** formed during the course of formation of **1--2** and **4--7**, respectively.](ao-2018-00782z_0001){#fig1}

The mechanism of cyclopalladation of *N*,*N*-dimethylbenzylamine, L, with Pd(OAc)~2~ in CHCl~3~ was investigated by Ryabov and co-workers.^[@ref31]^ The initially formed 1:2 adduct \[Pd(OAc)~2~L~2~\] was shown to dissociate one of the Ls, thereby generating a 14-electron three-coordinate T-shaped intermediate, \[Pd(OAc)~2~L\], with trans geometry around Pd(II) initially and then to cis geometry. The latter species undergoes cyclopalladation in the rate-determining step to afford a five-membered cyclopalladated amine, \[Pd{κ^2^(*C*,*N*)}(μ-OAc)\]~2~. Accordingly, we hypothesize that the intermediate **D** transforms to three-coordinate intermediate **F**, which subsequently transforms to another intermediate **G** before finally forming platinacycles such as **1** and **2**, as illustrated in [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}. The intermediate **G** upon cycloplatination can liberate weakly acidic AcOH, which would fail to protonate the nonplatinated guanidine, and hence, the imine N atom of nonplatinated guanidine would recoordinate to Pt(II) to afford **1** rather than forming an admixture of six-membered cycloplatinated guanidine, \[Pt{κ^2^(*C*,*N*)}(μ-OAc)\]~2~, and the guanidinium acetate. The intermediate **E** upon losing dimethyl sulfoxide (DMSO) can give rise to three-coordinate intermediate **H**, which upon trans → cis isomerization can give another three-coordinate intermediate **I**. The intermediate **I** upon cycloplatination can give rise to **4--7** (see [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}).
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Interestingly, the reaction of **8** with 1 equiv of NaOAc in MeOH under reflux condition for 8 h afforded a mixture of **1** and \[LH~3~^2-tolyl^\]Cl as colorless solids and **10** as pale green solid in low yields (see [Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}). In this reaction, perhaps all NaOAc was consumed to form **1** from 50% of **8** and the remaining 50% could have undergone cycloplatination to afford **10** and the guanidinium salt. The observance of three products in the aforementioned reaction helped us to reoptimize synthetic routes for **10** and **11** as described below.
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Complexes **8** and **9** were separately refluxed in methanol for 8 h to afford a mixture of **10** and \[LH~3~^2-tolyl^\]Cl and a mixture of **11** and \[LH~3~^2,4-xylyl^\]Cl, respectively (see [Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}). Crystals of **10** and **11** were separated from the respective guanidinium salts by the hand-pick method and further purified by crystallization from the CH~2~Cl~2~/toluene mixture at RT. It is to be noted that heating *trans*-\[PtCl~2~(APPY)~2~\] (APPY = acetylmethylenetriphenylphosphorane, Ph~3~PCHC(O)Me) in MeCN for 44 h afforded five-membered cycloplatinated ylide, \[Pt{κ^2^(*C*,*C*)}(μ-Cl)\]~2~, and the salt, APPYHCl.^[@ref32]^

It is to be noted that *trans*-\[PtCl~2~(DMSO){ArN=C(NHAr)~2~}\] (Ar = 2-MeC~6~H~4~) resisted cycloplatination in MeOH under reflux condition, while **8** and **9** underwent cycloplatination under identical condition to afford **10** and **11**, respectively, which suggests that the dissociated guanidine acts as a proton sponge, thereby driving the formation of respective platinacycles and the guanidinium salts instead of platinacycle **J** (see [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Putative cycloplatinated guanidines anticipated to form in [Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}.](ao-2018-00782z_0008){#fig2}

Adducts **8** and **9** upon reflux in MeOH can give rise to three-coordinate intermediates **K** and **L** with trans and cis geometry, respectively, around the Pt(II) atom (see [Scheme [8](#sch8){ref-type="scheme"}](#sch8){ref-type="scheme"}). The intermediate **L** upon cycloplatination could liberate strongly acidic HCl, which would protonate the imine N atom of nonplatinated guanidine to afford **10/11** and the respective guanidinium salts. The clean formation of **10/11** via this route is facilitated primarily because of the formation of stable guanidinium salts and their better solvation imparted by a polar protic solvent, MeOH. Thus, the structural motifs present in **1/2**, **4--7**, and **10/11** are influenced by a single or a combination of more than one of the following factors.1The degree of steric encumbrance around the Pt(II) atom in the precursors with sterically less hindered *cis*-\[Pt(OAc)~2~(DMSO)~2~\]/*trans*-\[PtCl~2~(PhCN)~2~\] permitting entry of two guanidines per Pt while sterically more hindered *cis*-\[Pt(TFA)~2~(DMSO)~2~\] permitting entry of only one guanidine per Pt.2The strength of acid liberated during the course of cycloplatination.3Influence of N--H···O hydrogen bond present in intermediates **F** and **G**. Noncovalent-directed syntheses of coordination compounds are an emerging area in synthetic inorganic/organometallic chemistry.^[@ref33]^
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Cycloplatinated guanidine **10** was poorly soluble in organic solvents, and this precluded its solution characterization by ^195^Pt and ^13^C NMR spectroscopy. Hence, **10** was derivatized with AgTFA in CH~2~Cl~2~ at RT for 24 h to afford more soluble **12** in 94% yield (see [Scheme [9](#sch9){ref-type="scheme"}](#sch9){ref-type="scheme"}).

![](ao-2018-00782z_0025){#sch9}

2.3. SCXRD Studies {#sec2.3}
------------------

Molecular structures of *cis*-\[Pt(TFA)~2~(DMSO)~2~\], **1**·1/2CH~2~Cl~2~/**3**, **4/7**, \[LH~3~^2-anisyl^\]TFA, **8**, **10/11**·C~7~H~8~, and **12**·CH~2~Cl~2~ have been determined by SCXRD and are shown in [Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}--[8](#fig8){ref-type="fig"}. In *cis*-\[Pt(TFA)~2~(DMSO)~2~\], the Pt(II) atom revealed cis geometry as anticipated due to more effective (d--d) π bonding in this geometry.^[@ref34]^ The bond parameters around the Pt(II) atom in *cis*-\[Pt(TFA)~2~(DMSO)~2~\] are comparable with those found in the related compound *cis*-\[Pt(TFA)~2~((*M*,*S*~*S*~,*S*~*S*~)-*p*-tolyl-binaso)\].^[@ref35]^ Interestingly, the molecular structures of both *cis*- and *trans*-\[Pd(TFA)~2~(*S*-DMSO)(*O*-DMSO)\] have been reported, wherein DMSO is shown to reveal linkage isomerism.^[@ref36],[@ref37]^

![Molecular structure of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] at 50% probability level. Hydrogen atoms have been removed for clarity.](ao-2018-00782z_0009){#fig3}

![Molecular structures of **1**·1/2CH~2~Cl~2~ and **3** at 50% probability level. The solvent molecule in the case of **1**·1/2CH~2~Cl~2~ has been removed, and only hydrogen atoms of the amino moieties are shown for clarity.](ao-2018-00782z_0010){#fig4}

![Molecular structures of **4** and **7** at 50% probability level. Only hydrogen atoms of the amino moieties are shown for clarity.](ao-2018-00782z_0011){#fig5}

![Molecular structures of \[LH~3~^2-anisyl^\]TFA and **8** at 50% probability level. Only relevant hydrogen atoms of the guanidine and the guanidinium salt are shown for clarity.](ao-2018-00782z_0012){#fig6}

![Molecular structures of **10** and **11**·C~7~H~8~ at 50% probability level. Toluene in **11**·C~7~H~8~ has been removed, and only hydrogen atoms of the amino moieties are shown for clarity.](ao-2018-00782z_0013){#fig7}

![Molecular structure of **12**·CH~2~Cl~2~ at 50% probability level. The solvent molecule has been removed, and only hydrogen atoms of the amino moieties are shown for clarity.](ao-2018-00782z_0014){#fig8}

In **1**·1/2CH~2~Cl~2~ and **3**, the Pt(II) atom is simultaneously a part of the six-membered \[Pt{κ^2^(*C*,*N*)}\] ring and the eight-membered \[Pt{κ^2^(*O*,*N*)}\] ring with the latter ring intramolecularly stabilized through \>N--H···O=C\< hydrogen bond involving one of the NH protons of the nonplatinated guanidine and carbonyl oxygen atom of OAc and TFA, respectively. The imine N atom of the nonplatinated guanidine is placed cis to the Pt--C bond of the *C*,*N* chelate, while OAc and TFA are placed cis to the Pt--N bond, and thus, the Pt(II) atom in both platinacycles revealed cisoid configuration.

The configuration of Pd(II)/Pt(II) atoms in cyclometallated N-donor ligands was explained by invoking steric factor and *antisymbiosis*/*transphobia* of two mutually trans-oriented ligands and the influence of the latter factor was independently verified in one study by theoretical calculations.^[@ref4],[@ref24],[@ref38]−[@ref40]^ The cisoid configuration of the Pt(II) atom in **1**·1/2CH~2~Cl~2~ and **3** is unfavorable from the point of view of degree of *transphobia*, as hard imine N atom of both the guanidines lies trans to each other. In a hypothetical transoid configuration such as that illustrated in **M**, there would be greater steric repulsion between 2-tolyl substituents of the imine N atom of both platinated and nonplatinated guanidines (see [Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}). Thus, steric factor overrides the degree of *transphobia* in deciding the geometry of the Pt(II) atom in **1**·1/2CH~2~Cl~2~ and **3**.

![Possible geometrical isomers of **1--3**.](ao-2018-00782z_0015){#fig9}

Intriguingly, the six-membered \[Pt{κ^2^(*C*,*N*)}\] ring is planar in both **1**·1/2CH~2~Cl~2~ and **3** and is coplanar with the fused platinated 2-tolyl ring with the dihedral angle between two six-membered rings being 0.8(2)° (**1**·1/2CH~2~Cl~2~) and 3.1(1)° (**3**). The prevalence of a planar six-membered \[Pd{κ^2^(*C*,*N*)}\] ring in six-membered cyclopalladated N-donor ligands was indicated and in one instance such a species was identified by variable concentration ^1^H NMR spectroscopy.^[@ref38],[@ref41]^ The nonplatinated guanidine in **1**·1/2CH~2~Cl~2~ and **3** revealed anti--anti conformation as reported for free LH~2~^2-tolyl^.^[@ref42]^

Unlike **1**·1/2CH~2~Cl~2~ and **3**, the six-membered \[Pt{κ^2^(*C*,*N*)}\] ring in **4** and **7** revealed a pseudo-boat conformation. The flagpole atoms Pt1 and N3 lie at 0.58(1) and 0.274(9) Å in **4** and at 0.62(1) and 0.26(1) Å in **7**, respectively, above the basal plane constituted by N1, C1, C16, and C17. The bond parameters around the Pt(II) atom in **4** and **7** are comparable with the respective parameters reported for five-membered cycloplatinated N-donor ligands, \[Pt{κ^2^(*C*,*N*)}(OC(O)R)(L)\] (R/L = Me/DMSO^[@cit43a]^ and CF~3~/DMS^[@cit43b]^).

The structure and bonding of the CN~3~ unit in cyclometallated *sym N*,*N*′,*N*″-triarylguanidines can be better understood from the value of ρ.^[@ref44]^ The ρ values for the structurally characterized compounds prepared in the present investigation are listed in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The lone pair of the amino N atoms can interact with the \>C=N-- π\* orbital of the guanidine moiety through n−π conjugation, and for a maximum n−π conjugation, the ρ value should be 1.0 and any downward deviation from this value indicates hampered n−π conjugation. The ρ values for new compounds listed in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} are much greater than the ρ value known for the respective free guanidines.^[@ref42]^ The ρ value of 1.00 for \[LH~3~^2-anisyl^\]TFA is as anticipated due to a maximum n−π conjugation, which arises because of the presence of a charge-delocalized Y-conjugated species (angle sum around CN~3~ carbon, ∑C ≈ 360°).^[@ref45]^ The amino N atoms of the guanidine moieties are planar (∑N ≈ 360°) in all compounds, further supporting enhanced n−π conjugation in all new compounds listed in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The greater ρ value for the C,N chelate in **3** than that observed for the same chelate in **1**·1/2CH~2~Cl~2~ is attributed to the presence of more electronegative TFA in the former complex. The greater ρ value for the *C*,*N* chelate in **11**·C~7~H~8~ than that observed for the same chelate in **10** is attributed to the stronger binding of the imine N atom of 2,4-xylyl guanidine moiety to the Pt(II) atom in the former. The cation and the anion in \[LH~3~^2-anisyl^\]TFA are linked by a pair of N--H···O hydrogen bonds and thus form an eight-membered ring characteristic of this type of salts.^[@ref46]^

###### Comparison of ρ Values of **1**·1/2CH~2~Cl~2~, **3**, **4**, **7**, \[LH~3~^2-anisyl^\]TFA, **8**, **10**, **11**·C~7~H~8~, and **12**·CH~2~Cl~2~[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-00782z_0026){#GRAPHIC-d7e2242-autogenerated}

  complex                  *a* (Å)                                                                             (*b* + *c*)/2 (Å)                                                                     ρ = 2*a*/(*b* + *c*)
  ------------------------ ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  **1**·1/2CH~2~Cl~s~      1.309(5)/1.312(5)[b](#t1fn2){ref-type="table-fn"}                                   1.343(7)/1.352(7)[b](#t1fn2){ref-type="table-fn"}                                     0.97/0.97[b](#t1fn2){ref-type="table-fn"}
  **3**                    1.317(5)/1.314(5)[b](#t1fn2){ref-type="table-fn"}                                   1.324(7)/1.358(7)[b](#t1fn2){ref-type="table-fn"}                                     0.99/0.97[b](#t1fn2){ref-type="table-fn"}
  **4**                    1.305(8)                                                                            1.337(12)                                                                             0.98
  **7**                    1.318(8)                                                                            1.348(13)                                                                             0.98
  \[LH~3~^2-anisyl^\]TFA   1.337(2)                                                                            1.338(3)                                                                              1.00
  **8**                    1.295(9)[b](#t1fn2){ref-type="table-fn"}/1.303(9)[b](#t1fn2){ref-type="table-fn"}   1.356(13)[b](#t1fn2){ref-type="table-fn"}/1.340(10)[b](#t1fn2){ref-type="table-fn"}   0.97[b](#t1fn2){ref-type="table-fn"}/0.97[b](#t1fn2){ref-type="table-fn"}
  **10**                   1.303(8)                                                                            1.336(11)                                                                             0.97
  **11**·C~7~H~8~          1.303(7)/1.322(7)                                                                   1.322(11)/1.338(10)                                                                   0.99/0.99
  **12**·CH~2~Cl~2~        1.302(8)/1.301(8)                                                                   1.330(11)/1.334(13)                                                                   0.98/0.97

ρ = 0.93 (LH~2~^2-tolyl^), 0.92 (LH~2~^2-anisyl^) and 0.93 (LH~2~^2,4-xylyl^).^[@ref42]^

The values indicated are for the nonplatinated guanidine.

Four distinct conformations, namely, trans syn syn--syn, trans syn syn--anti, trans syn anti--syn, and trans syn anti--anti, are possible for **8** and **9** depending upon (i) the disposition of the guanidine around the Pt(II) atom, (ii) the orientation of the \>C=N-- unit of one guanidine with respect to the orientation of the identical unit of the second guanidine, and (iii) the orientation of the aryl ring of the amino moieties with respect to the \>C=N-- unit of the guanidine (see [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00782/suppl_file/ao8b00782_si_001.pdf)).^[@ref30]^ Complex **8** revealed trans syn anti--anti conformation as sterically hindered 2-tolyl substituent of the amino moieties is better accommodated in this conformation. The observed conformation is further stabilized by a pair of intramolecular N--H···Cl hydrogen bonds and three intramolecular C--H···Cl hydrogen bonds. The bond parameters around the Pt(II) atom in **8** are comparable with those parameters reported for the related *trans*-\[PtCl~2~L~2~\] (L = ferrocenyl-based amidine and guanidine).^[@ref23],[@ref28]^

Cyclometallated five-membered N-donor ligands, \[M{κ^2^(*C*,*N*)}(μ-X)\]~2~ (M/X = Pd and Pt/Cl, Br, or I), are known to exist as either cisoid or transoid conformer in the solid state, but the former conformer is not possible for **10** and **11**·C~7~H~8~ as there would be a repulsive interaction between two =NAr units of the guanidine ligands. However, **10** and **11**·C~7~H~8~ can exist as five different conformers, namely, transoid syn planar, transoid anti planar, transoid syn puckered (or butterfly-like), transoid anti puckered (or bat-like), and transoid puckered, as illustrated in [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}. Transoid syn planar, transoid syn puckered, and transoid anti puckered possess a pseudo-*C*~2~ symmetry, which passes right across the center of the \[Pt(μ-Cl)~2~Pt\]^2+^ ring, while transoid anti planar possesses an inversion symmetry. Transoid puckered conformer does not possess any such symmetry.

![Possible conformers of **10** and **11·C~7~H~8~**.](ao-2018-00782z_0002){#fig10}

In the solid state, **10** revealed a transoid anti planar conformation, while **11**·C~7~H~8~ revealed transoid anti puckered conformation. Thus, the four-membered \[Pt(μ-Cl)~2~Pt\]^2+^ ring in **10** is planar, while that in **11**·C~7~H~8~ is puckered. The dihedral angle between two mean planes constituted by Pt1--Cl1--Cl1\# and Pt1\#--Cl1--Cl1\# triangles in **10** is 0.0(1)°, and the corresponding dihedral angle in **11**·C~7~H~8~ is 45.1(1)°. As a result, the nonbonded Pt···Pt distance, 3.6479(4) Å, in **10** is longer than the corresponding distance in **11**·C~7~H~8~ (3.3869(3) Å). The Pt--Cl1\# distance of 2.458(2) Å (**10**) and the corresponding distances of 2.458(1) Å, 2.449(1) Å (**11**·C~7~H~8~), both of which are trans to the Pt--C(aryl) bond, are longer than the second Pt--Cl distance(s) \[2.325(2) Å (**10**) and 2.324(1) Å and 2.326(1) Å (**11**·C~7~H~8~)\] because of greater trans influence of the platinated carbon of the aryl ring in the C,N chelate. It is to be noted that six-membered cyclopalladated 2-tolyl and 2,4-xylyl guanidines \[Pd{κ^2^(*C*,*N*)}(μ-Br)\]~2~ revealed transoid syn puckered and transoid anti puckered conformations, respectively.^[@ref39]^ The difference in the conformations of **10** and its Pd(II) counterpart probably arises because of the difference in size of the atoms in the \[M(μ-X)~2~M\]^2+^ (M/X = Pt/Cl and Pd/Br) ring and difference in the packing forces.

In principle, **12**·CH~2~Cl~2~ can exist as three different conformers, namely, transoid in--in, transoid in--out, and transoid out--out, as we have shown for six-membered cyclopalladated guanidines, \[Pd{κ^2^(*C*,*N*)}(μ-OC(O)R)\]~2~ (R = Me, CF~3~, and ^*t*^Bu).^[@ref38],[@ref39]^ In the solid state, **12**·CH~2~Cl~2~ revealed transoid in--in conformation as analogously revealed by six-membered cyclopalladated 2-tolyl- and 2,4-xylyl guanidines, \[Pd{κ^2^(*C*,*N*)}(μ-OAc)\]~2~.^[@ref39]^

Cyclometallated N-donor ligands are known since the pioneering work of Cope and Siekman who published their seminal paper in 1965.^[@ref47]^ A number of known structurally characterized five-membered cycloplatinated N-donor ligands of type **I** shown in [Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"} are greater than their six- and seven-membered counterparts.^[@ref1],[@ref9],[@ref12],[@cit15a],[@ref24],[@ref43],[@ref48]^ Further structurally characterized five-membered cycloplatinated N-donor ligands of types **II** and **III** are scarce,^[@ref2]−[@ref4],[@ref49]−[@ref52]^ while their six- and seven-membered counterparts are presently unknown. Thus, to the best of our knowledge, **10/11**·C~7~H~8~ and **12**·CH~2~Cl~2~ represent the first crystallographically characterized six-membered cycloplatinated N-donor ligands of types **II** and **III** to be reported in the literature. Further, **1**·1/2CH~2~Cl~2~ and **3** represent the first structurally characterized planar six-membered cyclometallated N-donor ligands of this kind to be reported in the literature.

![Structural motifs of known cycloplatinated N-donor ligands.](ao-2018-00782z_0003){#fig11}

2.4. Spectroscopic Characterization {#sec2.4}
-----------------------------------

### 2.4.1. Attenuated Total Reflection IR (ATR--IR) Spectroscopy {#sec2.4.1}

Pt(II) guanidine complexes prepared in the present investigation were characterized by IR and multinuclear NMR (^1^H, ^13^C, ^19^F, and ^195^Pt) spectroscopy, elemental analyses, and mass spectrometry. IR spectroscopy is a powerful tool to unambiguously assign the coordination modes of the carboxylate moiety in metal carboxylate complexes.^[@ref53]^ The IR spectrum of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] revealed two bands at 1722 and 1400 cm^--1^ assignable to ν~a~(OCO) and ν~s~(OCO), respectively. From the Δν = ν~a~(OCO) -- ν~s~(OCO) value of 322 cm^--1^ and from the fact that this value is greater than the Δν value reported for NaTFA (223 cm^--1^),^[@ref53]^ the presence of a monodentate coordination mode for TFA in *cis*-\[Pt(TFA)~2~(DMSO)~2~\] is confirmed. The IR spectrum of *cis*-\[Pt(TFA)~2~(DMSO)~2~\] also revealed a band at 1144 cm^--1^ assignable to the ν(SO) stretch of S-bonded DMSO.^[@ref37],[@ref54]^

The IR spectra of **1--3** revealed a pair of bands at 1622 and 1386 cm^--1^ (**1**·1/2CH~2~Cl~2~), 1624 and 1387 cm^--1^ (**2**), and 1676 and 1393 cm^--1^ (**3**) assignable to ν~a~(OCO) and ν~s~(OCO), respectively. The Δν values of 236, 237, and 283 cm^--1^ indicated the presence of hydrogen-bonded monodentate OAc^[@ref55]^ in **1**·1/2CH~2~Cl~2~ and **2** and hydrogen-bonded monodentate TFA in **3**, respectively. The Δν values of 326, 315, 310, and 322 cm^--1^ for **4--7**, respectively, indicated the presence of monodentately coordinated TFA, while the Δν value of 130 cm^--1^ for **12**·CH~2~Cl~2~ indicated the presence of bridging bidentately coordinated TFA. The IR spectra of all other new Pt(II) complexes and guanidinium salts prepared in the present investigation revealed bands at anticipated positions assignable to the ν(NH), ν(C=N), and ν(SO) stretches, whichever is applicable.

### 2.4.2. NMR Spectroscopy {#sec2.4.2}

The Me/OMe substituents in aryl rings of guanidines in new complexes reported in this manuscript are useful not only in modulating their solubility in low polar solvents but also in serving as the NMR (^1^H and ^13^C) spectroscopic handle to understand the number and nature of solution species. Further, different substitution patterns of aryl rings in guanidines afforded different information in solution, which enabled us to better interpret the number and nature of solution species.

^195^Pt NMR spectroscopy is a powerful technique to understand the coordination environment around the metal in platinum(II) complexes because of its favorable NMR properties.^[@ref56]^ Intramolecular cycloplatination of N-donor ligands results in upfield δ(^195^Pt) NMR shifts.^[@cit5b],[@ref12],[@ref24],[@ref56],[@ref57]^ Further, δ(^195^Pt) window is wider, covering about 6000 ppm interval, which permits one to distinguish even one set of geometrical isomers and conformers of \[*C*,*E*\] platinacycles (E = N and C) without any ambiguity.^[@ref24],[@ref40]^ Hence, the new complexes in solution were characterized by ^195^Pt NMR spectroscopy.

^195^Pt NMR spectra of *cis*-\[PtX~2~(DMSO)~2~\] (X = OAc and TFA) revealed a singlet at δ(^195^Pt) −3086 and −3094 ppm, respectively, and these values are more downfield-shifted than that reported for *cis*-\[PtCl~2~(DMSO)~2~\] (δ(^195^Pt) −3450 ppm^[@ref29]^) because of the presence of more electron-withdrawing carboxylate moieties in the former two complexes. ^195^Pt NMR spectra of **1--3** revealed a pair of signals for each platinacycle at δ(^195^Pt) −2784 and −2718 ppm (intensity ratio = 1.00:0.55), −2783 and −2724 ppm (intensity ratio = 1.00:0.62), and −2818 and −2879 ppm (intensity ratio = 1.00:0.75), respectively, revealing the presence of two solution species. ^1^H NMR spectra of **1** and **2** revealed the presence of two species in about 1.00:0.65 and 1.00:0.57 ratios, respectively, and the presence of two solution species is in agreement with the results obtained from ^13^C NMR spectroscopy (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00782/suppl_file/ao8b00782_si_001.pdf)). Interestingly, the ^1^H NMR spectrum of **3** revealed the presence of four species in about 1.00:0.69:0.23:0.10 ratio, and the presence of four solution species was further supported by ^13^C and ^19^F NMR spectroscopy.

From the foregoing discussion, we suggest the presence of a maximum of four solution species for **1--3**, and these four species are assigned to four conformers, namely, syn--syn, syn--anti, anti--syn, and anti--anti, as illustrated in [Figure [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"}. The nonplatinated guanidine in the solid-state isomer of **1** and **3** can decoordinate in solution to afford an acyclic intermediate **N** because of destabilizing *transphobia* effect (see [Figure [13](#fig13){ref-type="fig"}](#fig13){ref-type="fig"}). Subsequently, the nonplatinated guanidine in the intermediate **N** can undergo amine--imine tautomerization^[@ref58]^ to afford another intermediate **O**, which would recoordinate to the Pt(II) atom through the imine N atom to afford a mixture of conformers illustrated in [Figure [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"}. The aryl substituent of the N atoms, which are not involved in intramolecular N--H···O hydrogen bond in intermediates **N** and **O**, is free to undergo incremental N--C~aryl~ bond rotation, and hence, formation of three more conformers in addition to the solid-state conformer via intermediates **N** and **O** is likely possible.

![Possible conformers of **1--3** in solution. The substituents on the aryl rings have been removed for clarity.](ao-2018-00782z_0004){#fig12}

![Interconversion of intermediates **N** and **O** via amine--imine tautomerization.](ao-2018-00782z_0005){#fig13}

To better understand the nature and number of solution species of **1--3**, platinacycle **13** was isolated (see [Figure [14](#fig14){ref-type="fig"}](#fig14){ref-type="fig"}). The ^1^H NMR spectrum of **13** is anticipated to reveal the presence of only one conformer in solution because of the presence of more symmetrical 4-tolyl rings. Thus, the ^1^H NMR spectrum of **13** revealed six singlets in a 1:1:1:1:2:1 ratio for CH~3~ protons of tolyl rings and the acetate moiety (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00782/suppl_file/ao8b00782_si_001.pdf)). Further, a downfield-shifted signal was observed for the NH proton (δ = 11.42 ppm), which is involved in intramolecular N--H···O hydrogen bond. Thus, the ^1^H NMR spectrum of **13** clearly supported our hypothesis that more than one solution species of **1--3** arises from four distinct conformers illustrated in [Figure [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"}.

![Platinacycle **13** (Ar = 4-MeC~6~H~4~) which exists as a single isomer in solution.](ao-2018-00782z_0006){#fig14}

^195^Pt NMR spectra of **4--7** revealed one peak each at δ(^195^Pt) −3650, −3674, −3655, and −3657 ppm, respectively, indicating the presence of a single solution species, and this conclusion was independently verified by ^1^H, ^13^C, and ^19^F NMR spectroscopy. As anticipated, the δ(^195^Pt) value of **7** is deshielded than that reported for its chloro analogue, \[Pt{κ^2^(*C*,*N*)}Cl(DMSO)\] (δ(^195^Pt) −3737 ppm^[@ref24]^), because of the presence of more electron-withdrawing TFA in the former complex. The δ(^195^Pt) values reported for **4--7** are also upfield-shifted than that reported for five-membered cycloplatinated ferrocenylamine, \[Pt{κ^2^(*C*,*N*)}(OAc)(DMSO)\] (δ(^195^Pt) −2078 ppm^[@cit43a]^) not only due to the difference in the \[Pt{κ^2^(*C*,*N*)}\] ring size but also due to the difference in the nature of ligands. The presence of one solution species for **4** contrasts with the presence of seven solution species reported for its chloro analogue, \[Pt{κ^2^(*C*,*N*)}Cl(DMSO)\] (δ(^195^Pt) −2645 (minor), −2710 (major), −2760 (minor), −2839 (minor), −2851 (minor), −2958 (major), and −2995 (minor) ppm^[@ref24]^). This spectral difference in the number of solution species arises because of larger size of the TFA in platinacycle **4**. As a result, only one conformer, α3, out of six possible conformers (α1, α2, α3, β1, β2, and β3^[@ref24]^) is possible for **4** even in solution. The α and β nomenclature indicates conformers that arise due to three distinct orientations of DMSO with respect to the plane of the Pt(II) atom and two distinct orientations of the *o*-substituted aryl ring in the =NAr unit of the C,N chelate with respect to the basal plane of the boat, respectively.

The ^195^Pt NMR spectrum of **8** revealed one peak at δ(^195^Pt) −1799 ppm, while ^1^H NMR spectra measured in both CDCl~3~ and C~6~D~6~ revealed the presence of two species in about 1.00:0.66 and 1.00:0.50 ratios, respectively. The presence of two solution species for **8** in CDCl~3~ was also independently verified by ^13^C NMR spectroscopy. Complex **9** also revealed the presence of two solution species as revealed by ^195^Pt, ^1^H, and ^13^C spectroscopy (see [Experimental Section](#sec4){ref-type="other"}). The ^195^Pt NMR spectrum of **9** revealed two singlets at δ(^195^Pt) −1818 (minor) and −1804 (major) ppm, suggesting the presence of two solution species. The δ(^195^Pt) shifts observed for **8** and **9** are comparable with those shifts reported for the related 1:2 adducts (δ(^195^Pt) −1887, −2020, and −1872 ppm).^[@ref23],[@ref28],[@ref59]^ The major and minor solution species of **8** and **9** are assigned to trans syn anti--anti, the solid-state isomer, and trans syn anti--syn isomer with the latter isomer arising from the former via the restricted C--N(H)Ar single bond rotation, as illustrated in [Scheme [10](#sch10){ref-type="scheme"}](#sch10){ref-type="scheme"}.

![](ao-2018-00782z_0017){#sch10}

Two halves of the molecule in all conformers except transoid puckered for **10** and **11** are equivalent because of molecular symmetry (see [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}). We would expect a maximum of three singlets for CH~3~ protons of the guanidine ligand for **10** and a maximum of six singlets for the same protons of the guanidine for **11** when the conformers possess either *C*~2~ or inversion symmetry for each isomer assuming that there are no overlapping CH~3~ signals. The transoid puckered conformer is expected to reveal a maximum of 6 singlets for CH~3~ protons of the guanidine ligand for **10** and a maximum of 12 singlets for the same protons of the guanidine for **11** assuming that there are no overlapping CH~3~ signals.

Platinacycle **10** is only sparingly soluble in common deuterated NMR solvents, which precluded its characterization by ^195^Pt and ^13^C NMR spectroscopy. The ^1^H NMR spectrum of **10** in CDCl~3~ revealed the presence of three species in about 1.00:0.78:0.50 ratio as estimated from the integrals of CH~3~ protons of the guanidine ligand. The ^1^H NMR spectrum of **10** revealed three singlets for the first isomer, three singlets for the second isomer, and two singlets for the third isomer assignable to the CH~3~ protons, thus accounting for six Me groups of the guanidine ligand. Thus, the three isomers in solution possess either *C*~2~ or inversion symmetry. However, better solubility of **11** in common deuterated NMR solvents enabled us to characterize it by ^1^H, ^195^Pt, and ^13^C NMR spectroscopy. The ^195^Pt NMR spectrum of **11** revealed three peaks at δ(^195^Pt) −2863, −2854, and −2848, indicating the presence of three solution species. The three solution species observed for **10** and **11** contrasts with the single solution species reported for five-membered cycloplatinated imines, \[Pt{κ^2^(*C*,*N*)}(μ-Cl)\]~2~, which were shown to reveal a single δ(^195^Pt) shift (δ(^195^Pt) range: −3108 to −3165 ppm) in solution.^[@cit3b],[@cit3c]^

The ^1^H NMR spectrum of **11** in C~6~D~6~ revealed the presence of two species in about 1.00:0.96 ratio as estimated from the integrals of CH~3~ protons of the guanidine ligand. Five singlets were observed for CH~3~ protons of the guanidine moiety in one isomer (**11a**), and nine singlets were observed for the same protons of the second isomer (**11b**), thus accounting for 12 Me groups of the guanidine ligand, which clearly revealed that isomer **11a** possesses either *C*~2~ or inversion symmetry, while isomer **11b** does not possess either of the two. The ^1^H NMR spectrum of **11** in CDCl~3~ revealed the presence of three isomers **11a**, **11b**, and **11c** in about 1.00:1.13:0.91 ratio, respectively, as estimated from the integrals of CH~3~ protons of the ligand. The ^1^H NMR spectrum revealed four singlets for CH~3~ protons for both **11a** and **11c** while seven singlets for the same protons of **11b**, thus accounting for 12 Me groups of the guanidine ligand for each species. Thus, it appears that both isomers **11a** and **11c** possess either *C*~2~ symmetry or inversion symmetry or one of these symmetries. Further, isomer **11b** appears to possess neither *C*~2~ symmetry nor inversion symmetry, thereby referring to the transoid puckered conformer.

From the solution behavior of **11** in C~6~D~6~, we suggest the presence of any two conformers, one originating from either transoid syn puckered or transoid anti puckered and the other isomer arising from transoid puckered and the conformational equilibria in this case arise only due to the six-membered \[Pt{κ^2^(*C*,*N*)}\] ring inversion as C~6~D~6~ is noncoordinating. We suggest that the crystals of solid-state conformers upon dissolution in weakly coordinating CDCl~3~ undergo a bridge-splitting reaction to afford solvent-coordinated intermediates, **P** and **Q**, respectively, and these intermediates are free to undergo six-membered \[Pt{κ^2^(*C*,*N*)}\] ring inversion in solution before reforming any of the three conformers illustrated in [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"} (see also [Figure [15](#fig15){ref-type="fig"}](#fig15){ref-type="fig"}). The conformational equilibria in solution are made possible for **10** and **11** because the Pt--Cl bond, which is trans to the Pt--C bond, is weaker because of greater trans influence of the platinated carbon. ^1^H, ^195^Pt, and ^13^C NMR spectra of **12** in solution indicated the presence of a single species. The δ(^195^Pt) −2555 ppm value observed for **12** is downfield-shifted when compared to those δ(^195^Pt) shifts of **11** because of the presence of more electron-withdrawing TFA bridges in the former.

![Solvent-coordinated intermediates possibly formed in solution for **10** (**P**) and **11** (**Q**) in CDCl~3~ (Sol).](ao-2018-00782z_0007){#fig15}

3. Conclusions {#sec3}
==============

Cycloplatination of several guanidines with Pt(II) carboxylate precursors was reported under facile reaction condition without recourse to the use of an external base to afford either **1** and **2** or **4--7** depending upon the carboxylates in the precursors. Thermolysis of **8** and **9** in MeOH under reflux condition afforded cycloplatinated **10** and **11**, respectively. Complex **10** was further derivatized with AgTFA to afford **12**. The yields of all complexes except one complex are good to very good. The new complexes were characterized by analytical, IR, and multinuclear NMR (^1^H, ^13^C, ^19^F, and ^195^Pt) spectroscopic techniques, and the structural motifs present in 10 complexes were unambiguously determined by SCXRD. To the best of our knowledge, the structural motifs present in some of the new complexes are unprecedented in the literature. The number and nature of solution species of new complexes were identified by multinuclear NMR spectroscopy. We have shown that the steric factor of anions in Pt(II) precursors is critical in determining the course of cycloplatination and hence structural motifs of the products.

4. Experimental Section {#sec4}
=======================

All characterizations of the new compounds were carried out with batches of single crystals.

4.1. *cis*-\[Pt(TFA)~2~(DMSO)~2~\] {#sec4.1}
----------------------------------

*cis*-\[PtCl~2~(DMSO)~2~\] (50.0 mg, 0.118 mmol) and AgTFA (52.1 mg, 0.236 mmol) were taken in a 50 mL round-bottom (RB) flask covered with an Al foil. To the flask was added 35 mL CH~2~Cl~2~, and the reaction mixture was stirred for 24 h. Subsequently, the reaction mixture was filtered through a 0.2 μM syringe filter. The volatiles from the filtrate were removed under vacuum to afford the solid. The solid was subsequently dissolved in acetone and layered with ethanol, and the resulting solution was stored at RT for 3 days to afford the title complex as colorless crystals. Yield: 91% (62.0 mg, 0.107 mmol). mp 173.4 °C. ATR--IR (cm^--1^): ν~a~(OCO) 1722 (s); ν~s~(OCO) 1400 (m); ν(S=O) 1144 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 3.45 (s, 4 × 3 H, (C*H*~3~)~2~S(O)). ^1^H NMR (acetone-*d*~6~, 400 MHz): δ 3.60 (s, *J*~PtH~ = 9.4 Hz, 4 × 3 H, (C*H*~3~)~2~S(O)). ^19^F{^1^H} NMR (acetone-*d*~6~, 376.31 MHz): δ −75.65. ^195^Pt{^1^H} NMR (acetone-*d*~6~, 85.8 MHz): δ −3094. LRMS (EI) *m*/*z* \[ion\]: 736 \[M + Na + NaTFA\]^+^, 656 \[M + DMSO + H\]^+^, 578 \[M + H\]^+^, 464 \[M -- TFA\]^+^. Anal. Calcd for C~8~H~12~O~6~F~6~S~2~Pt (*M*~w~ 577.375): C, 16.64; H, 2.09; S, 11.11. Found: C, 16.62; H, 1.95; S, 11.33.

4.2. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-3(NHC(NHAr)(=NAr))-2}(OAc)(LH~2~^2-tolyl^)\] (Ar = 2-MeC~6~H~4~; **1**) {#sec4.2}
----------------------------------------------------------------------------------------------------------

*cis*-\[Pt(OAc)~2~(DMSO)~2~\] (50.0 mg, 0.107 mmol) and LH~2~^2-tolyl^ (71.2 mg, 0.216 mmol) were taken in a 25 mL RB flask, to which was added toluene (10 mL). The RB flask was fitted with a double surface condenser capped with a freshly prepared anhydrous CaCl~2~ guard tube. The reaction mixture was refluxed for 8 h, cooled, and filtered. The volume of the filtrate was reduced to about one-third and stored at RT for 1 week to afford **1** as colorless crystals. Crystals of **1**·1/2CH~2~Cl~2~ suitable for SCXRD were grown from a CH~2~Cl~2~/^*i*^Pr~2~O mixture at RT over a period of several days. Yield: 82% (80 mg, 0.088 mmol). Two additional procedures for the preparation of **1** are described later in this section.

mp 203.0 °C. ATR--IR (cm^--1^): ν(NH) 3418 (w), 3392 (w); ν~a~(OCO) 1622 (s); ν(C=N) 1591 (s), 1551 (s); ν~s~(OCO) 1386 (s). The ^1^H NMR spectrum of **1** revealed the presence of two isomers, which are hereafter indicated as isomers **1a** and **1b** in about 1.00:0.65 ratio as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.41 (s, 3H, C*H*~3~, isomer **1a**), 1.42, 1.63 (each s, 2 × 3H, C*H*~3~, isomer **1b**), 1.66, 1.97 (each s, 2 × 3H, C*H*~3~, isomer **1a**), 1.98 (s, 3H, C*H*~3~, isomer **1b**), 2.08 (s, 3H, C*H*~3~, isomer **1a**), 2.11 (s, 3H, C*H*~3~, isomer **1b**), 2.17 (s, 3H, C*H*~3~, isomer **1a**), 2.23, 2.34, 2.42 (each s, 3 × 3H, C*H*~3~, isomer **1b**), 2.47, 2.53 (each s, 2 × 3H, C*H*~3~, isomer **1a**), 5.53 (s, 1H, N*H*, isomer **1b**), 5.66 (s, 1H, N*H*, isomer **1a**), 5.70 (s, 2 × 1H, N*H*, isomers **1a** & **1b**), 6.47 (s, 1H, N*H*, isomer **1a**), 6.53 (s, 1H, N*H*, isomer **1b**), 6.57--7.04 (m, 2 × 12H, Ar*H*, isomers **1a** & **1b**), 7.10--7.32 (m, 19H, Ar*H*, isomer **1a** (11H) & isomer **1b** (8H)), 7.67 (dd, *J*~HH~ = 6.9 Hz, 2H, Ar*H*, isomer **1b**), 7.87 (d, *J*~HH~ = 8.4 Hz, 1H, Ar*H*, isomer **1b**), 10.54 (s, 1H, N*H*, isomer **1b**), 10.71 (s, 1H, N*H*, isomer **1a**). ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −2784 and −2718. LRMS (EI) *m*/*z* \[ion\]: 934 \[M + Na\]^+^. Anal. Calcd for C~46~H~48~N~6~O~2~Pt·H~2~O (*M*~w~ 930.004): C, 59.41; H, 5.42; N, 9.04. Found: C, 59.65; H, 5.18; N, 9.15.

4.3. \[Pt{κ^2^(*C*,*N*)-C~6~H~2~Me~2~-3,5(NHC(NHAr)(=NAr))-2}(OAc)(LH~2~^2,4-xylyl^)\] (Ar = 2,4-Me~2~C~6~H~3~; **2**) {#sec4.3}
----------------------------------------------------------------------------------------------------------------------

Complex **2** was prepared from *cis*-\[Pt(OAc)~2~(DMSO)~2~\] (50.0 mg, 0.107 mmol) and LH~2~^2,4-xylyl^ (80.3 mg, 0.216 mmol) in toluene (10 mL) and purified as described previously for complex **1**. Yield: 84% (90 mg, 0.090 mmol). mp 206.0 °C. ATR--IR (cm^--1^): ν(NH) 3411 (w), 3400 (sh); ν~a~(OCO) 1624 (s); ν(C=N) 1603 (s), 1544 (m); ν~s~(OCO) 1387 (m). The ^1^H NMR spectrum of **2** revealed the presence of two isomers, which are hereafter indicated as isomers **2a** and **2b** in about 1.00:0.57 ratio as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.377 (s, 3H, C*H*~3~, isomer **2a**), 1.409, 1.606 (each s, 2 × 3H, C*H*~3~, isomer **2b**), 1.632 (s, 3H, C*H*~3~, isomer **2a**), 1.840 (s, 3H, C*H*~3~, isomer **2b**), 1.948 (s, 3H, C*H*~3~, isomer **2a**), 2.003 (s, 3H, C*H*~3~, isomer **2b**), 2.037 (s, 3H, C*H*~3~, isomer **2a**), 2.056 (s, 2 × 3H, C*H*~3~, isomers **2a** & **2b**), 2.063 (s, 3H, C*H*~3~, isomer **2a**), 2.076 (s, 3H, C*H*~3~, isomer **2b**), 2.099 (s, 3H, C*H*~3~, isomer **2a**), 2.151 (s, 3H, C*H*~3~, isomer **2b**), 2.171 (s, 3H, C*H*~3~, isomer **2a**), 2.220, 2.253 (each s, 2 × 3H, C*H*~3~, isomer **2b**), 2.278 (s, 3H, C*H*~3~, isomer **2a**), 2.296 (s, 3 × 3H, C*H*~3~, isomer **2a** (6H) & isomer **2b** (3H)), 2.313, 2.348 (each s, 2 × 3H, C*H*~3~, isomer **2b**), 2.388 (s, 3H, C*H*~3~, isomer **2a**), 2.412 (s, 3H, C*H*~3~, isomer **2b**), 2.477 (s, 3H, C*H*~3~, isomer **2a**), 5.481 (s, 1H, N*H*, isomer **2b**), 5.627 (s, 2 × 1H, N*H*, isomer **2a**), 5.643 (s, 1H, N*H*, isomer **2b**), 6.368--6.425 (m, 2H, Ar*H* (isomer **2a**, 1H) & N*H* (isomer **2b**, 1H)), 6.524--6.644 (m, 8H, Ar*H* (isomer **2a**, 3H & isomer **2b**, 4H) & N*H* (isomer **2a**, 1H)), 6.721 (s, 1H, Ar*H*, isomer **2a**), 6.792--6.813 (m, 3H, Ar*H* (isomer **2a**, 2H & isomer **2b**, 1H)), 6.923--7.016 (m, 12H, Ar*H* (isomer **2a**, 4H & isomer **2b**, 8H)), 7.038 (s, 2H, Ar*H*, isomer **2a**), 7.081 (br, 2H, Ar*H*, isomer **2b**), 7.113 (s, 1H, Ar*H*, isomer **2a**), 7.136 (br, 1H, Ar*H*, isomer **2a**), 7.158 (s, 1H, Ar*H*, isomer **2b**), 7.442 (d, *J*~HH~ = 9.6 Hz, 2H, Ar*H*, isomer **2a**), 7.686 (d, *J*~HH~ = 8.4 Hz, 1H, Ar*H*, isomer **2b**), 10.237 (s, 1H, N*H*, isomer **2b**), 10.481 (s, 1H, N*H*, isomer **2a**). ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −2783 and −2724. LRMS (EI) *m*/*z* \[ion\]: 996 \[M + H\]^+^, 936 \[M -- OAc\]^+^. Anal. Calcd for C~52~H~60~N~6~O~2~Pt (*M*~w~ 996.147): C, 62.70; H, 6.07; N, 8.44. Found: C, 62.65; H, 6.14; N, 8.50.

4.4. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-3(NHC(NHAr)(=NAr))-2}(TFA)(LH~2~^2-tolyl^)\] (Ar = 2-MeC~6~H~4~; **3**) {#sec4.4}
----------------------------------------------------------------------------------------------------------

Complex **1** (100 mg, 0.110 mmol) and AgTFA (24.3 mg, 0.110 mmol) were taken in a 50 mL RB flask covered with an Al foil. To the flask was added CH~2~Cl~2~ (20 mL), and the mixture was stirred for 24 h. The reaction mixture was subsequently filtered through a 0.2 μM syringe filter. The volatiles from the filtrate were removed under vacuum to one-third of its original volume, layered with toluene (2 mL), and the resulting solution was stored at RT for a period of 1 week to afford **3** as colorless crystals. Yield: 94% (99.6 mg, 0.103 mmol). mp 240 °C. ATR--IR (cm^--1^): ν(NH) 3414 (w), 3395 (w); ν~a~(OCO) 1676 (s); ν(C=N) 1603 (s), 1589 (m); ν~s~(OCO) 1393 (m). The ^1^H NMR spectrum of **3** revealed the presence of four isomers, which are hereafter indicated as isomers **3a--d** in about 1.00:0.69:0.23:0.10 ratio as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.621 (s, 3H, C*H*~3~, isomer **3d**), 1.643 (s, 3H, C*H*~3~, isomer **3b**), 1.670 (s, 3H, C*H*~3~, isomer **3c**), 1.681 (s, 3H, C*H*~3~, isomer **3a**), 1.962 (s, 2 × 3H, C*H*~3~, isomers **3a** & **3c**), 1.974 (s, 2 × 3H, C*H*~3~, isomers **3b** & **3d**), 2.056, 2.065 (each s, 2 × 3H, C*H*~3~, isomer **3c**), 2.082 (s, 2 × 3H, C*H*~3~, isomers **3a** & **3c**), 2.107 (s, 3H, C*H*~3~, isomer **3b**), 2.135 (s, 3H, C*H*~3~, isomer **3a**), 2.182 (s, 3H, C*H*~3~, isomer **3b**), 2.269, 2.367 (each s, 2 × 3H, C*H*~3~, isomer **3d**), 2.400 (s, 3H, C*H*~3~, isomer **3a**), 2.415 (s, 3H, C*H*~3~, isomer **3b**), 2.422 (s, 2 × 3H, C*H*~3~, isomers **3b** & **3d**), 2.446 (s, 2 × 3H, C*H*~3~, isomers **3c** & **3d**), 2.475 (s, 3H, C*H*~3~, isomer **3a**), 5.406 (s, 1H, N*H*, isomer **3c**), 5.487 (s, 1H, N*H*, isomer **3d**), 5.623 (s, 1H, N*H*, isomer **3b**), 5.635 (s, 2 × 1H, N*H*, isomers **3a** & **3d**), 5.672 (s, 1H, N*H*, isomer **3b**), 5.776 (s, 1H, N*H*, isomer **3a**), 5.871, 6.392 (each s, 2 × 1H, N*H*, isomer **3c**), 6.449 (s, 2 × 1H, N*H*, isomers **3a** & **3d**), 6.496 (s, 1H, N*H*, isomer **3b**), 6.635--6.872 (m, 4 × 8H, Ar*H*, isomers **3a--d**), 6.911--7.280 (m, 56H, Ar*H*, isomers **3a** & **3b** (2 × 13H) & isomers **3c** & **3d** (2 × 15H)), 7.593 (d, *J*~HH~ = 7.2 Hz, 2H, Ar*H*, isomer **3a**), 7.649 (t, *J*~HH~ = 8.6 Hz, 2H, Ar*H*, isomer **3b**), 9.307 (s, 1H, N*H*, isomer **3d**), 9.484 (s, 1H, N*H*, isomer **3c**), 9.683 (s, 1H, N*H*, isomer **3b**), 9.839 (s, 1H, N*H*, isomer **3a**). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −73.94, −73.88, −73.66, −73.54. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −2818, −2879. LRMS (EI) *m*/*z* \[ion\]: 966 \[M + H\]^+^, 852 \[M -- TFA\]^+^. Anal. Calcd for C~46~H~45~N~6~O~2~F~3~Pt (*M*~w~ 965.96): C, 57.20; H, 4.70; N, 8.70. Found: C, 57.49; H, 4.74; N, 8.72.

4.5. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-3(NHC(NHAr)(=NAr))-2}(TFA)(DMSO)\] (Ar = 2-MeC~6~H~4~) (**4**) {#sec4.5}
-------------------------------------------------------------------------------------------------

*cis*-\[Pt(TFA)~2~(DMSO)~2~\] (50 mg, 0.087 mmol) and LH~2~^2-tolyl^ (29 mg, 0.088 mmol) were taken in a 25 mL RB flask, to which was added toluene (10 mL). The RB flask was fitted with a double surface condenser capped with a freshly prepared anhydrous CaCl~2~ guard tube. The reaction mixture was refluxed for 8 h, cooled, and filtered. The volume of the filtrate was reduced to about one-third of its original volume and stored at RT for 2 days to afford **4** as colorless crystals. Crystals suitable for SCXRD were grown from a mixture of CH~2~Cl~2~/cyclohexane at RT over a period of 3 days. Yield: 78% (48 mg, 0.068 mmol). mp 217.0 °C. ATR--IR (cm^--1^): ν(NH) 3391 (m); ν~a~(OCO) 1682 (s); ν(C=N) 1610 (m); ν~s~(OCO) 1358 (m); ν(S=O) 1120 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 1.66, 2.08, 2.33 (each s, 3 × 3 H, C*H*~3~), 3.13, 3.16 (each s, 2 × 3 H, (C*H*~3~)~2~S(O)), 6.21, 6.49 (each s, 2 × 1H, N*H*), 6.81 (d, *J*~HH~ = 4.8 Hz, 2H, Ar*H*), 7.18--7.24 (m, 4H, Ar*H*), 7.28--7.36 (m, 4H, Ar*H*), 7.79 (t, *J*~HH~ = 4.6 Hz; *J*~PtH~ = 29.2 Hz, 1H, Ar*H*). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −74.43. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −3650. LRMS (EI) *m*/*z* \[ion\]: 601 \[M -- TFA\]^+^. Anal. Calcd for C~26~H~28~N~3~O~3~F~3~SPt (*M*~w~ 714.656): C, 43.70; H, 3.95; N, 5.88; S, 4.49. Found: C, 43.66; H, 3.80; N, 5.69; S, 4.45.

4.6. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-5(NHC(NHAr)(=NAr))-2}(TFA)(DMSO)\] (Ar = 4-MeC~6~H~4~; **5**) {#sec4.6}
------------------------------------------------------------------------------------------------

Complex **5** was prepared from *cis*-\[Pt(TFA)~2~(DMSO)~2~\] (50.0 mg, 0.087 mmol) and LH~2~^4-tolyl^ (29 mg, 0.088 mmol) in toluene (10 mL) and purified as described previously for complex **4**. Yield: 73% (45 mg, 0.063 mmol). mp 166.0 °C. ATR--IR (cm^--1^): ν(NH) 3399 (w); ν~a~(OCO) 1682 (s); ν(C=N) 1611 (s); ν~s~(OCO) 1367 (m); ν(S=O) 1142 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 2.32, 2.33, 2.38 (each s, 3 × 3 H, C*H*~3~), 3.14 (s, 2 × 3 H, ((C*H*~3~)~2~S(O)), 6.36 (d, *J*~HH~ = 8.0 Hz, 1H, Ar*H*), 6.51, 6.52 (each s, 2 × 1H, N*H*), 6.82 (d, *J*~HH~ = 7.6 Hz, 1H, Ar*H*), 6.97 (d, *J*~HH~ = 8.4 Hz, 2H, Ar*H*), 7.12 (d, *J*~HH~ = 8.4 Hz, 2H, Ar*H*), 7.19 (d, *J*~HH~ = 8.4 Hz, 2H, Ar*H*), 7.24 (d, *J*~HH~ = 8.4 Hz, 2H, Ar*H*), 7.79 (s, *J*~PtH~ = 32.4 Hz, 1H, Ar*H*). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −74.69. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −3674. LRMS (EI) *m*/*z* \[ion\]: 601 \[M -- TFA\]^+^. Anal. Calcd for C~26~H~28~N~3~O~3~F~3~SPt (*M*~w~ 714.656): C, 43.70; H, 3.95; N, 5.88; S, 4.49. Found: C, 43.57; H, 3.94; N, 5.81; S, 4.56.

4.7. \[Pt{κ^2^(*C*,*N*)-C~6~H~2~Me~2~-3,5(NHC(NHAr)(=NAr))-2}(TFA)(DMSO)\] (Ar = 2,4-Me~2~C~6~H~3~; **6**) {#sec4.7}
----------------------------------------------------------------------------------------------------------

Complex **6** was prepared from *cis*-\[Pt(TFA)~2~(DMSO)~2~\] (50.0 mg, 0.087 mmol) and LH~2~^2,4-xylyl^ (33 mg, 0.088 mmol) in toluene (10 mL) and purified as described previously for complex **4**. Yield: 83% (55 mg, 0.072 mmol). mp 156.0 °C. ATR--IR (cm^--1^): ν(NH) 3404 (w); ν~a~(OCO) 1690 (m); ν(C=N) 1610 (m); ν~s~(OCO) 1380 (w); ν(S=O) 1134 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 1.65, 2.03, 2.25, 2.28, 2.30, 2.34 (each s, 6 × 3 H, C*H*~3~), 3.12, 3.15 (each s, 2 × 3 H, (C*H*~3~)~2~S(O)), 6.13, 6.41 (each s, 2 × 1H, N*H*), 6.62 (s, 1H, Ar*H*), 7.00--7.13 (m, 6H, Ar*H*), 7.60 (s, *J*~PtH~ = 31.6 Hz, 1H, Ar*H*). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −74.53. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −3655. LRMS (EI) *m*/*z* \[ion\]: 757 \[M + H\]^+^, 779 \[M + Na\]^+^, 643 \[M -- TFA\]^+^. Anal. Calcd for C~29~H~34~N~3~O~3~F~3~SPt·H~2~O (*M*~w~ 774.751): C, 44.96; H, 4.68; N, 5.42; S, 4.14. Found: C, 45.36; H, 4.56; N, 5.48; S, 4.20.

4.8. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~(OMe)-3(NHC(NHAr)(=NAr))-2}(TFA)(DMSO)\] (Ar = 2-(MeO)C~6~H~4~; **7**) {#sec4.8}
------------------------------------------------------------------------------------------------------

*cis*-\[Pt(TFA)~2~(DMSO)~2~\] (50.0 mg, 0.087 mmol) and LH~2~^2-anisyl^ (66.4 mg, 0.176 mmol) were taken in a 25 mL RB flask, to which was added toluene (10 mL). The RB flask was fitted with a double surface condenser capped with a freshly prepared anhydrous CaCl~2~ guard tube. The reaction mixture was refluxed for 8 h and cooled. The reaction mixture was filtered and stored at RT for 5 h to afford colorless crystals of \[LH~3~^2-anisyl^\]TFA on the walls of the container. Subsequently, these crystals were used for SCXRD and other characterization. The filtrate was further concentrated under vacuum to afford a white solid. The solid was dissolved in CH~2~Cl~2~ (2 mL), layered with ethanol (5 mL), and stored at RT for a period of 1 week to afford **7** as colorless crystals.

4.9. Complex **7** {#sec4.9}
------------------

Yield: 74% (49 mg, 0.064 mmol). mp 208.6 °C. ATR--IR (cm^--1^): ν(NH) 3370 (m); ν~a~(OCO) 1693 (m); ν(C=N) 1611 (s); ν~s~(OCO) 1371(m); ν(S=O) 1115 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 3.12, 3.18 (each br, 2 × 3 H, (C*H*~3~)~2~S(O)), 3.80, 3.87, 4.02 (each s, 3 × 3 H, OC*H*~3~), 6.69 (d, *J*~HH~ = 7.2 Hz, 1H, Ar*H*), 6.92--6.98 (m, 5H, Ar*H*), 7.14 (t, *J*~HH~ = 8.0 Hz, 1H, Ar*H*), 7.19--7.24 (m, 2H, Ar*H*), 7.29--7.31 (m, 1H, Ar*H*), 7.61 (d, *J*~HH~ = 8.4 Hz; *J*~PtH~ = 28.6 Hz, 1H, Ar*H*), 7.76, 7.99 (each s, 2 × 1H, N*H*). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −74.39. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −3657. LRMS (EI) *m*/*z* \[ion\]: 763 \[M + H\]^+^, 649 \[M -- TFA\]^+^, 571 \[M -- DMSO -- TFA\]^+^. Anal. Calcd for C~26~H~28~N~3~O~6~F~3~SPt (*M*~w~ 762.654): C, 40.95; H, 3.70; N, 5.51; S, 4.20. Found: C, 41.17; H, 3.46; N, 5.50; S, 4.11.

4.10. \[LH~3~^2-anisyl^\]TFA {#sec4.10}
----------------------------

Yield: 81% (35 mg, 0.070 mmol). mp 189 °C. ATR--IR (cm^--1^): ν~a~(OCO) 1679 (m); ν(C=N) 1639 (s); ν~s~(OCO) 1498 (m). ^1^H NMR (CDCl~3~, 400 MHz): δ 3.84 (s, 3 × 3H, OC*H*~3~), 6.70--6.75 (m, 6H, Ar*H*), 7.02 (t, *J*~HH~ = 7.6 Hz, 3H, Ar*H*), 7.10 (d, *J*~HH~ = 7.6 Hz, 3H, Ar*H*). The signal for NH protons was not observed. ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −75.29. HRMS (EI) *m*/*z* \[ion\]: 378 \[M -- TFA\]^+^. Anal. Calcd for C~24~H~24~N~3~O~5~F~3~ (*M*~w~ 491.459): C, 58.65; H, 4.92; N, 8.55. Found: C, 58.61; H, 4.55; N, 8.27.

4.11. *trans*-\[PtCl~2~{ArN=C(NHAr)~2~}~2~\] (Ar = 2-MeC~6~H~4~; **8**) {#sec4.11}
-----------------------------------------------------------------------

*trans*-\[PtCl~2~(PhCN)~2~\] (50.0 mg, 0.106 mmol) and LH~2~^2-tolyl^ (76.7 mg, 0.233 mmol) were taken in a 50 mL RB flask, to which was added toluene (15 mL). The RB flask was fitted with a double surface condenser capped with a freshly prepared anhydrous CaCl~2~ guard tube. The reaction mixture was refluxed for 48 h and cooled. The volatiles from the reaction mixture were removed under vacuum to afford a dull yellow brown solid. The solid was subjected to column chromatography on basic alumina with CHCl~3~ as the eluent. The fraction containing the title complex was concentrated under vacuum to 2 mL and left at RT for 1 week to afford **8** as bright orange yellow crystals, which was subsequently used for all characterization including SCXRD. Yield: 90% (88 mg, 0.095 mmol). mp 243.0 °C. ATR--IR (cm^--1^): ν(NH) 3377 (w), 3275 (w); ν(C=N) 1622 (m). ^1^H NMR spectra of **8** were measured in CDCl~3~ and C~6~D~6~, which revealed the presence of two species, which are hereafter indicated as isomers **8a** and **8b** in about 1.00:0.66 and 1.00:0.50 ratios, respectively, as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.91 (s, 2 × 3H, C*H*~3~, isomer **8a**), 1.93 (s, 4 × 3H, C*H*~3~, isomers **8a** & **8b**), 2.00 (s, 2 × 3H, C*H*~3~, isomer **8b**), 2.48 (s, 2 × 3H, C*H*~3~, isomer **8a**), 2.52 (s, 2 × 3H, C*H*~3~, isomer **8b**), 5.55 (s, 2 × 2H, N*H*, isomers **8a** & **8b**), 6.71--6.90 (m, 2 × 12H, Ar*H*, isomers **8a** & **8b**), 6.99--7.06 (m, 2 × 6H, Ar*H*, isomers **8a** & **8b**), 7.12 (br, 2 × 4H, Ar*H*, isomers **8a** & **8b**), 7.78 (t, *J*~HH~ = 8.8 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 8.54 (s, 2 × 2H, N*H*, isomers **8a** & **8b**). ^1^H NMR (C~6~D~6~, 400 MHz): δ 1.41 (s, 2 × 3H, C*H*~3~, isomer **8a**), 1.48 (s, 2 × 3H, C*H*~3~, isomer **8b**), 1.98 (s, 2 × 3H, C*H*~3~, isomer **8a**), 2.00 (s, 2 × 3H, C*H*~3~, isomer **8b**), 2.70 (s, 2 × 3H, C*H*~3~, isomer **8a**), 2.74 (s, 2 × 3H, C*H*~3~, isomer **8b**), 5.53 (s, 2 × 1H, N*H*, isomer **8b**), 5.57 (s, 2 × 1H, N*H*, isomer **8a**), 6.39 (d, *J*~HH~ = 7.6 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 6.45 (t, *J*~HH~ = 7.4 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 6.56--6.59 (m, 2 × 6H, Ar*H*, isomers **8a** & **8b**), 6.70--6.71 (br, 4H, Ar*H*, isomers **8a** & **8b**), 6.79 (broad t, *J*~HH~ = 6.4 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 6.86 (broad d, *J*~HH~ = 7.6 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 6.95 (br, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 7.02 (d, *J*~HH~ = 6.4 Hz, 2H, Ar*H*, isomer **8b**), 7.13--7.20 (m, 6H, Ar*H*, 4H (isomer **8a**) & 2H (isomer **8b**)), 8.37 (d, *J*~HH~ = 6.8 Hz, 2 × 2H, Ar*H*, isomers **8a** & **8b**), 9.10 (s, 2 × 2H, N*H*, isomers **8a** & **8b**). ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −1799. LRMS (ESI) *m*/*z* \[ion\]: 852 \[{M -- (2HCl)} + H\]^+^, 930 \[M + Li\]^+^. Anal. Calcd for C~44~H~46~N~6~Cl~2~Pt (*M*~w~, 924.8780): C, 57.14; H, 5.01; N, 9.09. Found: C, 57.25; H, 4.75; N, 9.01.

4.12. Reactivity of **8** {#sec4.12}
-------------------------

### 4.12.1. Method 1 {#sec4.12.1}

Complex **8** (100 mg, 0.108 mmol) and AgOAc (37.0 mg, 0.220 mmol) were taken in a 50 mL RB flask covered with an Al foil. To the flask was added CH~2~Cl~2~ (20 mL), and the mixture was stirred for 24 h. Subsequently, the reaction mixture was filtered through a 0.2 μM syringe filter. The volatiles from the filtrate were removed under vacuum to one-third of its original volume and layered with toluene (2 mL), and the resulting solution was stored at RT for a period of 1 week to afford **1** as colorless crystals. Yield: 90% (90 mg, 0.097 mmol).

### 4.12.2. Method 2 {#sec4.12.2}

Complex **8** (100 mg, 0.108 mmol) and NaOAc (19.5 mg, 0.238 mmol) were taken in a 50 mL RB flask, to which was added methanol (20 mL), and the resulting mixture was refluxed for 8 h. The reaction mixture was cooled, and volatiles were removed under vacuum to afford a solid. The solid was dissolved in CH~2~Cl~2~ (20 mL), and the insoluble material was filtered off. The filtrate was further concentrated under vacuum to about 3 mL, layered with toluene (3 mL), and stored at RT for 1 week to afford **1** as colorless crystals. Yield: 90% (89 mg, 0.097 mmol).

4.13. *trans*-\[PtCl~2~{ArN=C(NHAr)~2~}~2~\] (Ar = 2,4-Me~2~C~6~H~3~; **9**) {#sec4.13}
----------------------------------------------------------------------------

Complex **9** was prepared from the reaction of *trans*-\[PtCl~2~(PhCN)~2~\] (50.0 mg, 0.106 mmol) and LH~2~^2,4-xylyl^ (86.6 mg, 0.233 mmol) in toluene (15 mL) and purified by the procedure as described previously for **8**. The reaction mixture was subjected to column chromatography on basic alumina and eluted with chloroform. The fraction containing the title complex was concentrated under vacuum to afford oil, which was dissolved in *n*-hexane (5 mL) and left at RT for 4 days to afford **9** as dull orange yellow crystals. Yield: 45% (48 mg, 0.048 mmol). mp 230.0 °C. ATR--IR (cm^--1^): ν(NH) 3391 (w), 3300 (w); ν(C=N) 1597 (s). ^1^H NMR spectra of **9** in CDCl~3~ and C~6~D~6~ revealed the presence of two isomers, which are hereafter indicated as isomers **9a** and **9b** in about 1.00:0.80 and 1.00:0.63 ratios, respectively, as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.86 (s, 4 × 3H, C*H*~3~, isomers **9a** & **9b**), 1.93 (s, 2 × 3H, C*H*~3~, isomer **9a**), 1.98 (s, 2 × 3H, C*H*~3~, isomer **9b**), 2.06, 2.14, 2.21 (each s, 12 × 3H, C*H*~3~, isomers **9a** & **9b**), 2.41 (s, 2 × 3H, C*H*~3~, isomer **9a**), 2.44 (s, 2 × 3H, C*H*~3~, isomer **9b**), 5.44 (s, 2 × 2H, N*H*, isomers **9a** & **9b**), 6.60 (d, *J*~HH~ = 5.6 Hz, 2 × 6H, Ar*H*, isomers **9a** & **9b**), 6.66 (d, *J*~HH~ = 8.4 Hz, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 6.82--6.92 (m, 2 × 8H, Ar*H*, isomers **9a** & **9b**), 7.61 (t, *J*~HH~ = 8.4 Hz, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 8.36 (s, 2 × 2H, N*H*, isomers **9a** & **9b**). ^1^H NMR (C~6~D~6~, 400 MHz): δ 1.51 (s, 2 × 3H, C*H*~3~, isomer **9a**), 1.57 (s, 2 × 3H, C*H*~3~, isomer **9b**), 1.73, 1.88, 1.96 (each s, 12 × 3H, C*H*~3~, isomers **9a** & **9b**), 2.07 (s, 2 × 3H, C*H*~3~, isomer **9a**), 2.09 (s, 2 × 3H, C*H*~3~, isomer **9b**), 2.74 (s, 2 × 3H, C*H*~3~, isomer **9a**), 2.76 (s, 2 × 3H, C*H*~3~, isomer **9b**), 5.57 (s, 2 × 1H, N*H*, isomer **9b**), 5.61 (s, 2 × 1H, N*H*, isomer **9a**), 6.25 (s, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 6.43 (br, 2 × 4H, Ar*H*, isomers **9a** & **9b**), 6.56 (br, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 6.69 (s, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 6.81 (d, *J*~HH~ = 7.2 Hz, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 7.02--7.13 (m, 2 × 4H, Ar*H*, isomers **9a** & **9b**), 8.31 (d, *J*~HH~ = 8.0 Hz, 2 × 2H, Ar*H*, isomers **9a** & **9b**), 9.06 (s, 2 × 2H, N*H*, isomers **9a** & **9b**). ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −1818, −1804. LRMS (ESI) *m*/*z* \[ion\]: 936 \[{M -- (2HCl)} + H\]^+^, 1008 \[M + H\]^+^. Anal. Calcd for C~50~H~58~N~6~Cl~2~Pt (*M*~w~, 1009.017): C, 59.52; H, 5.79; N, 8.33. Found: C, 59.25; H, 5.73; N, 8.40.

4.14. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-3(NHC(NHAr)(=NAr))-2}(μ-Cl)\]~2~ (Ar = 2-MeC~6~H~4~; **10**) {#sec4.14}
------------------------------------------------------------------------------------------------

Complex **8** (100 mg, 0.108 mmol) was dispersed in methanol (20 mL) in a 50 mL RB flask, and the resulting heterogeneous mixture was refluxed for 8 h and cooled. During the course of the reaction, yellow solid slowly disappeared with concomitant formation of pale green solid. The volatiles from the reaction mixture were evaporated under vacuum to afford a solid. The solid was dissolved in CH~2~Cl~2~ (20 mL), concentrated under vacuum to about 3 mL, layered with toluene (6 mL), and stored at RT for 1 week to afford **10** as light green crystals and \[LH~3~^2-tolyl^\]Cl as white raisin-like solid. Compound **10** was separated from the mixture by the hand-pick method, and both **10** and the salt were recrystallized from CH~2~Cl~2~/toluene mixture at RT separately over a period of 1 week. These crystals were subsequently used for other characterization including SCXRD in the case of **10**.

4.15. Complex **10** {#sec4.15}
--------------------

Yield: 93% (56 mg, 0.050 mmol). mp 295.0 °C. ATR--IR (cm^--1^): ν(NH) 3402 (w), 3379 (w); ν(C=N) 1624 (s). The ^1^H NMR spectrum of **10** revealed the presence of three isomers, which are hereafter indicated as isomers **10a--c** in about 1.00:0.78:0.50 ratio as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.62 (s, 4 × 3H, C*H*~3~, isomers **10b** & **10c**), 1.63 (s, 2 × 3H, C*H*~3~, isomer **10a**), 2.12 (s, 6 × 3H, 2 × 3H (isomer **10a**), 4 × 3H (isomer **10c**), C*H*~3~), 2.32 (s, 2 × 3H, C*H*~3~, isomer **10a**), 2.44, 2.45 (each s, 4 × 3H, C*H*~3~, isomer **10b**), 5.67 (s, 2 × 1H, N*H*, isomer **10a**), 5.72 (s, 2 × 1H, N*H*, isomer **10c**), 5.73 (s, 2 × 1H, N*H*, isomer **10b**), 6.37 (br, 3 × 2H, N*H*, isomers **10a--c**), 6.58 (t, *J*~HH~ = 7.4 Hz, 2 × 2H, Ar*H*, isomers **10a** & **10b**), 6.65--6.70 (m, 11H, isomers **10a** & **10b** (2 × 3H) & isomer **10c** (5H), Ar*H*), 7.01--7.19 (m, 3 × 9H, Ar*H*, isomers **10a--c**), 7.22--7.32 (br, 22H, isomers **10a** & **10c** (2 × 8H) & isomer **10b** (6H), Ar*H*), 7.44 (d, *J*~HH~ = 7.2 Hz, 2H, Ar*H*, isomer **10b**). LRMS (ESI) *m*/*z* \[ion\]: 1119 \[M + H\]^+^. Anal. Calcd for C~44~H~44~N~6~Cl~2~Pt~2~ (*M*~w~ 1117.921): C, 47.27; H, 3.97; N, 7.52. Found: C, 46.99; H, 3.81; N, 7.38.

4.16. \[LH~3~^2-tolyl^\]Cl {#sec4.16}
--------------------------

Yield: 91% (36 mg, 0.098 mmol). mp 249.0 °C. ATR--IR (cm^--1^): ν(NH) 3120 (w, sh), 3030 (br, w); ν(C=N) 1620 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 2.35 (s, 3 × 3H, C*H*~3~), 7.00--7.06 (m, 12H, Ar*H*), 11.18 (br, 3 × 1H, N*H*). LRMS (ESI) *m*/*z* \[ion\]: 330 \[M -- Cl\]^+^. Anal. Calcd for C~22~H~24~N~3~Cl (*M*~w~ 365.898): C, 72.22; H, 6.61; N, 11.48. Found: C, 72.43; H, 6.41; N, 11.48.

4.17. \[Pt{κ^2^(*C*,*N*)-C~6~H~2~Me~2~-3,5(NHC(NHAr)(=NAr))-2}(μ-Cl)\]~2~ (Ar = 2,4-Me~2~C~6~H~3~; **11**) {#sec4.17}
----------------------------------------------------------------------------------------------------------

Compound **11** was prepared from **9** (100 mg, 0.100 mmol) and purified following the procedure reported previously for **10**. Single crystals of **11**·C~7~H~8~ were grown from a mixture of CH~2~Cl~2~/toluene at RT over a period of 4 days.

4.18. Complex **11** {#sec4.18}
--------------------

Yield: 96% (57 mg, 0.048 mmol). mp 277.0 °C. ATR--IR (cm^--1^): ν(NH) 3408 (w), 3340 (sh); ν(C=N) 1626 (s). The ^1^H NMR spectrum of **11** in C~6~D~6~ revealed the presence of two isomers, which are hereafter indicated as isomers **11a** and **11b** in about 1.00:0.96 ratio as estimated from the integrals of CH~3~ protons. ^1^H NMR (C~6~D~6~, 400 MHz, 0.0011 M): δ 1.490 (s, 2 × 3H, C*H*~3~, isomer **11b**), 1.509 (s, 2 × 3H, C*H*~3~, isomer **11a**), 1.554 (s, 2 × 3H, C*H*~3~, isomer **11b**), 1.575, 1.584 (each s, 2 × 3H, C*H*~3~, isomer **11b**), 1.916 (s, 4 × 3H, C*H*~3~, isomer **11a**), 2.096 (s, 2 × 3H, C*H*~3~, isomer **11b**), 2.210, 2.357, 2.368 (each s, 6 × 3H, C*H*~3~, isomer **11a**), 2.441, 2.447, 2.508, 2.537 (each s, 4 × 3H, C*H*~3~, isomer **11b**), 5.321 (s, 2 × 1H, N*H*, isomer **11a**), 5.348, 5.351 (each s, 2 × 1H, N*H*, isomer **11b**), 6.159, 6.169 (each s, 2 × 1H, N*H*, isomer **11b**), 6.194, 6.198 (each br, 2 × 1H, N*H*, isomer **11a**), 6.366--6.420 (m, 3H, Ar*H*, isomer **11a** (2H) & isomer **11b** (1H)), 6.481--6.583 (m, 2 × 5H, Ar*H*, isomers **11a** & **11b**), 6.915--7.067 (m, 4H, Ar*H*, isomer **11a** (1H) & isomer **11b** (3H)), 7.116--7.204 (m, 11H, Ar*H*, isomer **11a** (6H) & isomer **11b** (5H)), 7.356 (br, 2H, Ar*H*, isomers **11a** & **11b**), 7.705--7.722 (m, 1H, Ar*H*, isomer **11a**), 7.947 (br, 1H, Ar*H*, isomer **11b**).

The ^1^H NMR spectrum of **11** in CDCl~3~ revealed the presence of three isomers, which are hereafter indicated as isomers **11a--c** in about 1.00:1.13:0.91 ratio, respectively, as estimated from the integrals of CH~3~ protons. ^1^H NMR (CDCl~3~, 400 MHz): δ 1.60 (s, 4 × 3H, C*H*~3~, isomer **11c**), 1.61, 2.06 (each s, 4 × 3H, C*H*~3~, isomer **11b**), 2.07, 2.10 (each s, 8 × 3H, C*H*~3~, isomer **11a**), 2.17, 2.25, 2.26 (each s, 4 × 3H, C*H*~3~, isomer **11b**), 2.31 (s, 4 × 3H (isomer **11c**), 2 × 3H (isomer **11b**), C*H*~3~), 2.32, 2.33 (each s, 4 × 3H, C*H*~3~, isomer **11a**), 2.37 (s, 2 × 3H, C*H*~3~, isomer **11b**), 2.40, 2.44 (each s, 4 × 3H, C*H*~3~, isomer **11c**), 5.62 (s, 2 × 1H, N*H*, isomer **11b**), 5.67 (s, 2 × 1H, N*H*, isomer **11c**), 5.69 (s, 2 × 1H, N*H*, isomer **11a**), 6.29 (d, *J*~HH~ = 6.0 Hz, 3 × 2H, Ar*H*, isomers **11a--c**), 6.49 (d, *J*~HH~ = 7.6 Hz, 3 × 2H, Ar*H*, isomers **11a--c**), 6.86 (d, *J*~HH~ = 7.2 Hz, 3 × 1H, Ar*H*, isomers **11a--c**), 6.91--7.08 (m, 33H, Ar*H* (3 × 9 H) & N*H* (3 × 2 H), isomers **11a--c**), 7.15 (d, *J*~HH~ = 8.0 Hz, 2 × 2H, Ar*H*, isomers **11a** & **11b**), 7.22 (d, *J*~HH~ = 4.8 Hz, 2H, Ar*H*, isomer **11c**). ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −2863, −2854, −2848. LRMS (ESI) *m*/*z* \[ion\]: 1766 \[Pt{κ^2^(*C*,*N*)}(μ-Cl)\]~3~ -- Cl\]^+^, 1239 \[M + K\]^+^, 1223 \[M + Na\]^+^, 1201 \[M + H\]^+^, 1165 \[M -- Cl\]^+^, 623 \[Pt{κ^2^(*C*,*N*)}(μ-Cl)\]~2~/2 + Na\]}^+^. Anal. Calcd for C~50~H~56~N~6~Cl~2~Pt~2~·1/4C~7~H~8~ (*M*~w~ 1225.114): C, 50.73; H, 4.77; N, 6.86. Found: C, 50.84; H, 5.06; N, 6.68.

4.19. \[LH~3~^2,4-xylyl^\]Cl {#sec4.19}
----------------------------

Yield: 92% (37 mg, 0.092 mmol). mp 241.0 °C. ATR--IR (cm^--1^): ν(NH) 3150 (br, w); ν(C=N) 1624 (s). ^1^H NMR (CDCl~3~, 400 MHz): δ 2.19 (s, 3 × 3H, C*H*~3~), 2.29 (br, 3 × 3H, C*H*~3~), 6.76--6.87 (m, 3 × 3H, Ar*H*), 11.01 (br, 3 × 1H, N*H*). LRMS (ESI), *m*/*z* \[ion\]: 372 \[M -- Cl\]^+^. Anal. Calcd for C~25~H~30~N~3~Cl. (*M*~w~ 407.978): C, 73.60; H, 7.41; N, 10.30. Found: C, 74.03; H, 7.19; N, 9.99.

4.20. \[Pt{κ^2^(*C*,*N*)-C~6~H~3~Me-3(NHC(NHAr)(=NAr))-2}(μ-TFA)\]~2~ (Ar = 2-MeC~6~H~4~; **12**) {#sec4.20}
-------------------------------------------------------------------------------------------------

Complex **10** (55 mg, 0.049 mmol) and AgTFA (22 mg, 0.098 mmol) were taken in a 50 mL RB flask covered with an Al foil. To the flask was added CH~2~Cl~2~ (20 mL), and the mixture was stirred at RT for 24 h. The reaction mixture was filtered through a 0.2 μM syringe filter. The volatiles from the filtrate were evaporated under vacuum to one-third its original volume, layered with toluene (2 mL), and the resulting solution was stored at RT for a period of 1 week to afford **12**·CH~2~Cl~2~ as yellowish green crystals. Yield: 94% (59 mg, 0.046 mmol). mp 269 °C. ATR--IR (cm^--1^): ν(NH) 3420 (w) and 3381 (w); ν~a~(OCO) 1670 (s); ν(C=N) 1628 (s), 1599 (m); ν~s~(OCO) 1540 (m). ^1^H NMR (CDCl~3~, 400 MHz): δ 1.76, 1.90, 2.49 (each s, 6 × 3H, C*H*~3~), 5.41 (s, 2 × 1H, N*H*), 6.22 (d, *J*~HH~ = 8.0 Hz, 2H, Ar*H*), 6.32 (s, 2 × 1H, N*H*), 6.84 (d, *J*~HH~ = 7.2 Hz, 2H, Ar*H*), 6.90--6.94 (m, 6H, Ar*H*), 7.06 (t, *J*~HH~ = 7.4 Hz, 2H, Ar*H*), 7.17--7.24 (m, 8H, Ar*H*), 7.45--7.47 (m, 2H, Ar*H*). ^19^F{^1^H} NMR (CDCl~3~, 376.31 MHz): δ −74.33. ^195^Pt{^1^H} NMR (CDCl~3~, 85.8 MHz): δ −2555. Anal. Calcd for C~48~H~44~N~6~O~4~F~6~Pt~2~·1.25H~2~O (*M*~w~ 1295.564): C, 44.50; H, 3.62; N, 6.49. Found: C, 44.87; H, 3.34; N, 6.11.
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